Upgrade to SI Premium - Free Trial

CorMedix (CRMD)

7.79 +0.22 (2.91%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/11/26)

Latest Headlines

Form 8-K CorMedix Inc. For: Oct 19 October 19, 2026 8:00 AM - SEC Filing FDA grants priority review to CorMedix's Rezzayo fungal prophylaxis sNDA October 19, 2026 7:31 AM - StreetInsider Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases October 19, 2026 7:31 AM - Globe NewsWire Actinium Pharmaceuticals names Matt David as CFO October 15, 2026 7:31 AM - StreetInsider Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer October 15, 2026 7:30 AM - PR NewsWire Oppenheimer Starts CorMedix (CRMD) at Outperform September 23, 2026 6:08 AM - StreetInsider Form 4 CorMedix Inc. For: Sep 18 Filed by: Dillione Janet September 18, 2026 9:37 PM - SEC Filing CorMedix (CRMD) PT Raised to $14 at RBC Capital August 14, 2026 8:41 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on CorMedix (CRMD) August 14, 2026 6:50 AM - StreetInsider Today's Stocks in the News August 13, 2026 12:28 PM - StreetInsider Form 10-Q CorMedix Inc. For: Jun 30 August 13, 2026 8:08 AM - SEC Filing CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance August 13, 2026 7:33 AM - StreetInsider Form 8-K CorMedix Inc. For: Aug 13 August 13, 2026 7:32 AM - SEC Filing Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update August 13, 2026 7:30 AM - Globe NewsWire Form 8-K CorMedix Inc. For: Aug 07 August 7, 2026 4:20 PM - SEC Filing CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026 July 29, 2026 8:30 AM - Globe NewsWire Full Article List